佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

688198 佰仁医疗

交易中 12-20 09:54:46

{"stockData":{"symbol":"688198","market":"SH","secType":"STK","nameCN":"佰仁医疗","latestPrice":116.88,"timestamp":1734659686000,"preClose":114.52,"halted":0,"volume":29055,"delay":0,"floatShares":137000000,"shares":137000000,"eps":0.7537,"marketStatus":"交易中","marketStatusCode":2,"change":2.36,"latestTime":"12-20 09:54:46","open":115.86,"high":117.2,"low":115.34,"amount":3389600,"amplitude":0.0162,"askPrice":117.13,"askSize":2,"bidPrice":116.77,"bidSize":8,"shortable":0,"etf":0,"ttmEps":0.7537,"tradingStatus":2,"nextMarketStatus":{"tag":"午间休市","tradingStatus":4,"beginTime":1734665400000},"adr":0,"adjPreClose":114.52,"symbolType":"stock_kcb","openAndCloseTimeList":[[1734658200000,1734665400000],[1734670800000,1734678000000]],"highLimit":125.97,"lowLimit":103.07,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":137395148,"pbRate":13.43,"roa":"--","roe":"4.97%","epsLYR":0.85,"committee":0.276596,"marketValue":16059000000,"floatMarketCap":16059000000,"peRate":155.07496,"changeRate":0.0206,"turnoverRate":0.0002,"status":0},"requestUrl":"/m/hq/s/688198","defaultTab":"news","newsList":[{"id":"2486645763","title":"佰仁医疗最新公告：眼科生物补片注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2486645763","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486645763?lang=zh_cn&edition=full","pubTime":"2024-11-28 16:09","pubTimestamp":1732781366,"startTime":"0","endTime":"0","summary":"佰仁医疗公告，公司研发的眼科生物补片产品注册申请获国家药品监督管理局正式受理。该产品用于后巩膜加固术（PSR）以防治病理性近视，是患者防盲止盲唯一可采取的有效方法。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024112800024424.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2486366715","title":"佰仁医疗(688198.SH)：眼科生物补片注册申请获得受理的","url":"https://stock-news.laohu8.com/highlight/detail?id=2486366715","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486366715?lang=zh_cn&edition=full","pubTime":"2024-11-28 15:42","pubTimestamp":1732779773,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗 发布公告，近日，公司研发的眼科生物补片产品注册申请获国家药品监督管理局正式受理。特别是，其粘弹性有助于眼底神经元功能恢复，在后巩膜局部的生物相容性不仅能够满足患者术后短期的后巩膜组织重构要求，还能满足长期组织重塑的需求，最终帮助患者获得一个新的加厚的自身后巩膜，只有这样方可助力PSR获得远期理想的治疗效果，以切实解决中国病理性近视的治疗难题，给广大患者带来福音。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1217163.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2486663523","title":"佰仁医疗11月28日主力资金流出57万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2486663523","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486663523?lang=zh_cn&edition=full","pubTime":"2024-11-28 15:19","pubTimestamp":1732778392,"startTime":"0","endTime":"0","summary":"11月28日, 佰仁医疗股价跌1.16%，报收118.72元，成交金额1946万元，换手率0.12%，振幅2.01%，量比0.72。佰仁医疗今日主力资金净流出57万元，连续3日净流出，上一交易日主力净流出124万元，今日环比减少54.03%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为60.00%，平均跌幅为1.70%。该股近5个交易日下跌2.30%，主力资金累计净流出46万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出639万元，其中净流出天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128153339abe53a96&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241128153339abe53a96&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2486387128","title":"1-10月医保统筹收入稳增长，机构：医药后市反转源于三大机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2486387128","media":"汇添富基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486387128?lang=zh_cn&edition=full","pubTime":"2024-11-28 08:11","pubTimestamp":1732752682,"startTime":"0","endTime":"0","summary":"消息面上，据医保局日前披露，2024年1-10月医保统筹基金收入23065.07亿元，同比增长8.9%；2024年1-10月统筹支出19165.88亿元，同比增长8.9%。对此，国泰君安表示，1-10月医保统筹基金运行平稳，收入稳健增长，支出增速逐月收窄。国金证券表示，由于多方面因素，医药板块景气度在2021年后经历了长时间的下行。2024年11月7日，国家医保局召开了座谈会，强调了全国统一医保平台和大数据赋能商保发展的重要性。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2024112807590598e4504f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["600721","603108","BK0185","688163","603087","600976","600351","603858","600436","603939","688575","600380","600998","688331","603309","688266","600200","688278","600055","605199","603392","600161","600521","BK0070","600572","688192","688276","603439","600771","688506","688315","603567","600511","BK0096","688298","688356","600329","688193","600332","688581","688180","688336","600851","688076","688139","688198","600196","603127","600085","600129","688656","600080","603301","603658","600566","688373","688189","688067","605177","BK0012","600867","688221","688050","688488","688578","688687","688212","688105","688301","688670","600056","688046","688382","688091","688389","603456","688062","688085","603707","688566","600739","688235","688247","688428","600079","600062","688520","600763","603882","BK0239","688177","159938","603259","600252","603538","603896","688029","600420","688117","688658","688073","688351","BK0188","688222","688137","601607","688202","603590","600422","600535","688626","BK0028","688114","688176","600529","688690","600276","688443","600211","600285","688617","688767","688271","688321","688166","603367","603233","688161","600488"],"gpt_icon":0},{"id":"2486881697","title":"佰仁医疗11月27日遭主力抛售124万元 环比增加148.00%","url":"https://stock-news.laohu8.com/highlight/detail?id=2486881697","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2486881697?lang=zh_cn&edition=full","pubTime":"2024-11-27 15:20","pubTimestamp":1732692033,"startTime":"0","endTime":"0","summary":"11月27日, 佰仁医疗股价涨2.98%，报收120.11元，成交金额3290万元，换手率0.20%，振幅4.65%，量比1.06。佰仁医疗今日主力资金净流出124万元，上一交易日主力净流出50万元，今日环比增加148.00%。该股近5个交易日下跌1.70%，主力资金累计净流入47万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流出658万元，其中净流出天数为10日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127153259a2591f91&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241127153259a2591f91&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2484133822","title":"佰仁医疗股价涨5% 新品注册获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484133822","media":"智选洞察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484133822?lang=zh_cn&edition=full","pubTime":"2024-11-20 10:12","pubTimestamp":1732068753,"startTime":"0","endTime":"0","summary":"11月20日，佰仁医疗股价大幅上涨，截至10点12分，佰仁医疗上涨5.07%，报123.00元/股，成交1732万元，换手率0.10%，振幅4.55%。消息解读11月19日晚，佰仁医疗公告称，公司研发的心包膜注册申请已获国家药品监督管理局正式受理。资金动向截止发稿，佰仁医疗获得主力净流入249万元，其中超大单流入275万元，大单流出25万元。最新财报显示，今年三季报，佰仁医疗实现营业收入2.92亿元，同比增长13.57%，净利润为5,869.34万元，同比减少16.56%，基本每股收益为0.43元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101312a2473d9d&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241120101312a2473d9d&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2484999452","title":"佰仁医疗心包膜注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2484999452","media":"财中社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484999452?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:59","pubTimestamp":1732003140,"startTime":"0","endTime":"0","summary":"财中社11月19日电佰仁医疗 发布关于自愿披露心包膜注册申请获得受理的公告。公司研发的心包膜注册申请已获得国家药品监督管理局正式受理，受理号为CQZ2402086。尽管该产品的注册和上市有望改变心外ePTFE植入材料完全依赖进口的现状，但公司表示其能否通过注册审批仍存在不确定性，未来业绩的影响也无法预测。2024年前三季度，佰仁医疗实现收入2.92亿元，归母净利润5869万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119160229a2451b6f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241119160229a2451b6f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2484995324","title":"佰仁医疗(688198.SH)：心包膜(ePTFE)注册申请获受理 或将打破外企垄断实现国产自主可控","url":"https://stock-news.laohu8.com/highlight/detail?id=2484995324","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484995324?lang=zh_cn&edition=full","pubTime":"2024-11-19 15:39","pubTimestamp":1732001981,"startTime":"0","endTime":"0","summary":"智通财经APP讯，佰仁医疗(688198.SH)发布公告，公司研发的心包膜(ePTFE)注册申请获国家药品监督管理局正式受理，该产品为经特殊工艺加工制造的膨体聚四氟乙烯(ePTFE)膜，用于心脏外科手术中心包膜的修复或重建。据悉，目前国内市场所用的心包膜均为外企垄断，长期以来依赖进口，预期该产品的注册和上市将结束心外ePTFE植入材料全部进口的历史，实现国产自主可控。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212773.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2484626764","title":"佰仁医疗：11月15日高管金磊增持股份合计7625股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484626764","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484626764?lang=zh_cn&edition=full","pubTime":"2024-11-18 20:01","pubTimestamp":1731931284,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月18日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年11月15日公司董事,高级管理人员,核心技术人员金磊共增持公司股份7625.0股，占公司总股本为0.0055%。变动期间公司股价下跌2.47%，11月15日当日收盘报117.03元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111800028301.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2483322360","title":"佰仁医疗：11月14日高管金磊增持股份合计1.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483322360","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483322360?lang=zh_cn&edition=full","pubTime":"2024-11-15 20:01","pubTimestamp":1731672097,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月15日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年11月14日公司董事金磊共增持公司股份1.2万股，占公司总股本为0.0087%。变动期间公司股价下跌3.83%，11月14日当日收盘报120.0元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024111500038427.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2481424391","title":"佰仁医疗：分体式介入二尖瓣已经进入以注册为目的的动物试验阶段","url":"https://stock-news.laohu8.com/highlight/detail?id=2481424391","media":"财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2481424391?lang=zh_cn&edition=full","pubTime":"2024-11-08 16:39","pubTimestamp":1731055189,"startTime":"0","endTime":"0","summary":"近日，佰仁医疗举办2024年第三季度业绩说明会。经导管主动脉瓣系统基于佰仁医疗独有的专利创新技术设计，传承了经大组长期临床验证的瓣膜卓越耐久性，适配未来接续治疗的支架二次可扩性，优化了瓣膜病全生命周期管理。公司分体式介入二尖瓣已经进入以注册为目的的动物试验阶段，进展顺利，按规定和进程应在明年一至二季度完成术后观察，依据试验结果制定临床试验方案和计划临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108164003a22383ee&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241108164003a22383ee&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2480301720","title":"佰仁医疗：11月1日高管金磊增持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2480301720","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2480301720?lang=zh_cn&edition=full","pubTime":"2024-11-04 20:01","pubTimestamp":1730721687,"startTime":"0","endTime":"0","summary":"证券之星消息，根据11月4日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年11月1日公司董事,高级管理人员,核心技术人员金磊共增持公司股份2000.0股，占公司总股本为0.0015%。佰仁医疗近半年内的董监高及核心技术人员增减持详情如下：佰仁医疗的高管列表及最新持股情况如下：融资融券数据显示该股近5日融资净流出624.94万，融资余额减少；融券净流入0.0，融券余额增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024110400028279.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2479083685","title":"佰仁医疗：10月30日高管金磊增持股份合计2000股","url":"https://stock-news.laohu8.com/highlight/detail?id=2479083685","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479083685?lang=zh_cn&edition=full","pubTime":"2024-10-31 20:01","pubTimestamp":1730376076,"startTime":"0","endTime":"0","summary":"证券之星消息，根据10月31日市场公开信息、上市公司公告及交易所披露数据整理，佰仁医疗最新董监高及相关人员股份变动情况：2024年10月30日公司董事,高级管理人员,核心技术人员金磊共增持公司股份2000.0股，占公司总股本为0.0015%。变动期间公司股价下跌1.63%，10月30日当日收盘报120.82元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100040916.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2479295726","title":"中银证券：给予佰仁医疗买入评级","url":"https://stock-news.laohu8.com/highlight/detail?id=2479295726","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479295726?lang=zh_cn&edition=full","pubTime":"2024-10-31 14:40","pubTimestamp":1730356845,"startTime":"0","endTime":"0","summary":"中银国际证券股份有限公司刘恩阳,薛源近期对佰仁医疗进行研究并发布了研究报告《收入端增速稳定，看好新产品未来业绩增量》，本报告对佰仁医疗给出买入评级，当前股价为119.84元。最新盈利预测明细如下：该股最近90天内共有4家机构给出评级，买入评级4家；过去90天内机构目标均价为111.83。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103100023985.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["601696","688198"],"gpt_icon":0},{"id":"2479349562","title":"图解佰仁医疗三季报：第三季度单季净利润同比减10.04%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479349562","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479349562?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:20","pubTimestamp":1730222409,"startTime":"0","endTime":"0","summary":"证券之星消息，佰仁医疗2024年三季报显示，公司主营收入2.92亿元，同比上升13.57%；归母净利润5869.34万元，同比下降16.56%；扣非净利润5531.16万元，同比下降10.85%；其中2024年第三季度，公司单季度主营收入1.02亿元，同比上升13.25%；单季度归母净利润2350.27万元，同比下降10.04%；单季度扣非净利润2274.76万元，同比下降5.83%；负债率9.27%，投资收益763.21万元，财务费用-376.45万元，毛利率88.56%。财报数据概要请见下图:以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024103000000739.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198"],"gpt_icon":0},{"id":"2479312912","title":"佰仁医疗公布三季报 前三季净利减少16.56%","url":"https://stock-news.laohu8.com/highlight/detail?id=2479312912","media":"新浪财经-鹰眼工作室","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2479312912?lang=zh_cn&edition=full","pubTime":"2024-10-30 01:10","pubTimestamp":1730221800,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！ 　　10月30日消息，佰仁医疗发布三季度报告。　　公告显示，公司前三季度营业收入292,324,016.69元，同比增加13.57%，归属上市公司股东的净利润58,693,362.23元，同比减少16.56%。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：小浪快报","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/ggzz/2024-10-30/doc-incufzcn1642571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2478175860","title":"佰仁医疗最新公告：胶原纤维填充剂-I注册申请获得受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2478175860","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478175860?lang=zh_cn&edition=full","pubTime":"2024-10-28 16:25","pubTimestamp":1730103913,"startTime":"0","endTime":"0","summary":"佰仁医疗公告，控股子公司北京艾佰瑞生物技术有限公司研制的胶原纤维填充剂-I注册申请获国家药品监督管理局正式受理。以上内容为证券之星据公开信息整理，由智能算法生成，不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024102800020219.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688198","BK0251"],"gpt_icon":0},{"id":"2478676785","title":"佰仁医疗10月25日主力资金流出299万元 连续5日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2478676785","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2478676785?lang=zh_cn&edition=full","pubTime":"2024-10-25 15:18","pubTimestamp":1729840730,"startTime":"0","endTime":"0","summary":"10月25日, 佰仁医疗股价涨0.54%，报收127.37元，成交金额3414万元，换手率0.20%，振幅2.69%，量比0.47。佰仁医疗今日主力资金净流出299万元，连续5日净流出，上一交易日主力净流出267万元，今日环比增加11.99%。近一年数据显示，该股主力连续5日净流出后，次日下跌概率为25.00%，平均跌幅为0.66%。该股近5个交易日下跌4.41%，主力资金累计净流出1567万元，其中2个交易日为股价上涨时净流出；近20日主力资金累计净流出7327万元，其中净流出天数为12日。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153143ab72bea7&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241025153143ab72bea7&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0},{"id":"2477841980","title":"科技打头阵，如何低门槛布局科创板？","url":"https://stock-news.laohu8.com/highlight/detail?id=2477841980","media":"博时基金","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2477841980?lang=zh_cn&edition=full","pubTime":"2024-10-22 07:55","pubTimestamp":1729554913,"startTime":"0","endTime":"0","summary":"多家A股半导体行业上市公司披露了2024年前三季度业绩预告，业绩普遍预喜。科创100指数ETF只需要开通上海证券交易所基金账户，且满足交易风险评级要求，即可参与交易。ETF基金的过往业绩及其净值高低并不预示其未来业绩表现。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241022075245971a1755&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688063","688105","688153","688387","688276","688281","688516","688331","688409","688006","159982","688027","688110","688235","688289","688106","688336","688001","688050","688037","688055","688772","688639","688400","688582","688139","688029","688052","688390","688352","688208","688432","688062","688005","688002","688192","688549","688361","688017","688608","688717","688439","688520","688147","688066","688578","688327","688198","688617","688739","688248","688100","688536","688408","688141","688232","688007","688083","688019","688443","688326","688567","688686","688172","688526","688318","688612","688166","688779","688484","688568","688348","688702","688498","688425","688690","688278","688097","688146","688548","688333","688575","688778","688789","688107","000698","688322","688016","688161","688343","588030","688213","688433","688556","688700","688032","688200","688366","688048","688798","688266","688088","688347","688177"],"gpt_icon":0},{"id":"2476447925","title":"佰仁医疗大幅上涨 获主力净流入434万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2476447925","media":"智选洞察","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2476447925?lang=zh_cn&edition=full","pubTime":"2024-10-18 13:13","pubTimestamp":1729228401,"startTime":"0","endTime":"0","summary":"10月18日，佰仁医疗股价大幅上涨，截至13点13分，佰仁医疗上涨5.42%，报129.65元/股，成交6544万元，换手率0.38%。资金动向截止发稿，佰仁医疗获得主力净流入434万元，其中超大单流入989万元，大单流出555万元。最新财报显示，今年中报，佰仁医疗实现营业收入1.91亿元，同比增长13.74%，净利润为3,519.07万元，同比减少20.42%，基本每股收益为0.26元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018132438ab6b09b1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241018132438ab6b09b1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0251","688198"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2019-12-09","address":"北京市昌平区科技园东区华昌路2号","stockEarnings":[{"period":"1week","weight":-0.0342},{"period":"1month","weight":-0.0218},{"period":"3month","weight":0.1967},{"period":"6month","weight":0.1174},{"period":"1year","weight":-0.0719},{"period":"ytd","weight":-0.0736}],"companyName":"北京佰仁医疗科技股份有限公司","boardCode":"AI0035","perCapita":"55919股","boardName":"专用设备制造业","registeredCapital":"13739万元","compareEarnings":[{"period":"1week","weight":-0.0264},{"period":"1month","weight":0.0072},{"period":"3month","weight":0.2314},{"period":"6month","weight":0.124},{"period":"1year","weight":0.1612},{"period":"ytd","weight":0.1328}],"survey":"　　北京佰仁医疗科技股份有限公司是国内技术领先的、专注于动物源性植介入医疗器械研发与生产的高新技术企业,主要产品主要包括心脏瓣膜置换与修复、先天性心脏病植介入治疗、外科软组织修复等。","serverTime":1734659690520,"listedPrice":23.68,"stockholders":"2457人(较上一季度减少1.64%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"佰仁医疗,688198,佰仁医疗股票,佰仁医疗股票老虎,佰仁医疗股票老虎国际,佰仁医疗行情,佰仁医疗股票行情,佰仁医疗股价,佰仁医疗股市,佰仁医疗股票价格,佰仁医疗股票交易,佰仁医疗股票购买,佰仁医疗股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"佰仁医疗(688198)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供佰仁医疗(688198)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}